Industry
Biotechnology
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:07 am
Portfolio Pulse from Nina Zdinjak
August 12, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 4:53 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 10:04 am
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 3:21 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 6:51 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.